X.A. Alvarez

2.2k total citations
55 papers, 1.8k citations indexed

About

X.A. Alvarez is a scholar working on Neurology, Pharmacology and Physiology. According to data from OpenAlex, X.A. Alvarez has authored 55 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Neurology, 13 papers in Pharmacology and 12 papers in Physiology. Recurrent topics in X.A. Alvarez's work include Neurological Disorders and Treatments (26 papers), Neurological Disease Mechanisms and Treatments (16 papers) and Alzheimer's disease research and treatments (11 papers). X.A. Alvarez is often cited by papers focused on Neurological Disorders and Treatments (26 papers), Neurological Disease Mechanisms and Treatments (16 papers) and Alzheimer's disease research and treatments (11 papers). X.A. Alvarez collaborates with scholars based in Spain, Romania and United States. X.A. Alvarez's co-authors include Ramón Cacabelos, L. Fernández‐Novoa, José Javier Miguel-Hidalgo, G. Quack, Herbert Moessler, Carolina Sampedro, José Carlos Caamaño, Victor Pichel, Manuel Aleixandre and M. S. Barquero and has published in prestigious journals such as Biological Psychiatry, Brain Research and Annals of the New York Academy of Sciences.

In The Last Decade

X.A. Alvarez

53 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
X.A. Alvarez Spain 21 934 718 376 331 274 55 1.8k
L. Fernández‐Novoa Spain 22 562 0.6× 660 0.9× 455 1.2× 341 1.0× 174 0.6× 73 1.7k
D. Larry Sparks United States 22 909 1.0× 1.2k 1.6× 419 1.1× 173 0.5× 468 1.7× 41 2.4k
Elina Zotova United Kingdom 6 564 0.6× 1.1k 1.6× 389 1.0× 346 1.0× 195 0.7× 7 1.5k
Claire J. Garwood United Kingdom 22 752 0.8× 1.1k 1.5× 675 1.8× 191 0.6× 417 1.5× 32 1.9k
Beatriz Gomez Perez‐Nievas Spain 25 634 0.7× 987 1.4× 730 1.9× 361 1.1× 512 1.9× 38 2.2k
Jessica L. Restivo United States 11 452 0.5× 1.1k 1.5× 679 1.8× 279 0.8× 423 1.5× 14 1.9k
Raquel Sánchez‐Varo Spain 20 905 1.0× 1.2k 1.7× 469 1.2× 161 0.5× 463 1.7× 31 1.9k
Beatrice Hauss‐Wegrzyniak United States 22 823 0.9× 642 0.9× 449 1.2× 214 0.6× 391 1.4× 31 1.7k
Maud Gratuze United States 21 965 1.0× 1.1k 1.5× 444 1.2× 143 0.4× 360 1.3× 32 1.9k
Michael Hüll Germany 18 366 0.4× 744 1.0× 578 1.5× 361 1.1× 273 1.0× 41 1.6k

Countries citing papers authored by X.A. Alvarez

Since Specialization
Citations

This map shows the geographic impact of X.A. Alvarez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by X.A. Alvarez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites X.A. Alvarez more than expected).

Fields of papers citing papers by X.A. Alvarez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by X.A. Alvarez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by X.A. Alvarez. The network helps show where X.A. Alvarez may publish in the future.

Co-authorship network of co-authors of X.A. Alvarez

This figure shows the co-authorship network connecting the top 25 collaborators of X.A. Alvarez. A scholar is included among the top collaborators of X.A. Alvarez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with X.A. Alvarez. X.A. Alvarez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alvarez, X.A., Charisse N. Winston, James W. Barlow, et al.. (2022). Modulation of Amyloid-β and Tau in Alzheimer’s Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil. Journal of Alzheimer s Disease. 90(2). 705–717. 18 indexed citations
2.
Alvarez, X.A., Thinh N. Le, Thang Huy Nguyen, et al.. (2021). Clinical Efficacy of Cerebrolysin and Cerebrolysin plus Nootropics in the Treatment of Patients with Acute Ischemic Stroke in Vietnam. CNS & Neurological Disorders - Drug Targets. 21(7). 621–630. 6 indexed citations
3.
Alvarez, X.A., Irene Álvarez, Jesús Figueroa, et al.. (2016). Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. The International Journal of Neuropsychopharmacology. 19(6). pyw024–pyw024. 32 indexed citations
4.
Alvarez, X.A., Carlos Sánchez‐Linares, & Eliezer Masliah. (2012). Combination Drug Therapy for the Treatment of Alzheimer’s Disease. European Neurological Review. 7(2). 92–92. 6 indexed citations
5.
Alvarez, X.A. & Patricio Fuentes. (2011). Cerebrolysin in Alzheimer's disease. Drugs of today. 47(7). 487–487. 34 indexed citations
6.
Rockenstein, Edward, Kiren Ubhi, Sarah Michael, et al.. (2011). Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research. 89(11). 1812–1821. 18 indexed citations
7.
Alvarez, X.A., Ramón Cacabelos, Carolina Sampedro, et al.. (2011). Combination Treatment in Alzheimers Disease: Results of a Randomized, Controlled Trial with Cerebrolysin and Donepezil. Current Alzheimer Research. 8(5). 583–591. 46 indexed citations
8.
Mureșanu, Dafin F., X.A. Alvarez, Herbert Moessler, et al.. (2010). Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: Results of a 3-month extension study. Journal of the Neurological Sciences. 299(1-2). 179–183. 20 indexed citations
9.
Alvarez, X.A., Carolina Sampedro, Ramón Cacabelos, et al.. (2009). Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent Cerebrolysin. The International Journal of Neuropsychopharmacology. 12(7). 867–867. 28 indexed citations
10.
Alvarez, X.A., Lola Corzo, Carolina Sampedro, et al.. (2005). Neuropeptide dietary supplement N-PEP-12 enhances cognitivefunction and activates brain bioelectrical activity in healthyelderly subjects. Methods and Findings in Experimental and Clinical Pharmacology. 27(7). 483–483. 6 indexed citations
11.
12.
Miguel-Hidalgo, José Javier, X.A. Alvarez, Ramón Cacabelos, & G. Quack. (2002). Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40). Brain Research. 958(1). 210–221. 222 indexed citations
13.
Alvarez, X.A., Valter Lombardi, Lola Corzo, et al.. (2000). Oral Cerebrolysin® enhances brain alpha activity and improves cognitive performance in elderly control subjects. PubMed. 59. 315–328. 20 indexed citations
14.
Alvarez, X.A., Carolina Sampedro, Rafael Lozano, & Ramón Cacabelos. (1999). Citicoline protects hippocampal neurons against apoptosis inducedby brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods and Findings in Experimental and Clinical Pharmacology. 21(8). 535–535. 65 indexed citations
15.
Alvarez, X.A., L. Fernández‐Novoa, José Carlos Caamaño, et al.. (1997). Cerebrovascular Changes Associated with Interleukin‐1β (IL‐1β) and Histamine (HA) Levels in Alzheimer's Disease. Annals of the New York Academy of Sciences. 826(1). 375–378. 7 indexed citations
16.
Cacabelos, Ramón, et al.. (1996). Therapeutic Effects of CDP‐Choline in Alzheimer's Disease‐Cognition, Brain Mapping, Cerebrovascular Hemodynamics, and Immune Factorsa. Annals of the New York Academy of Sciences. 777(1). 399–403. 61 indexed citations
17.
Fernández‐Novoa, L., et al.. (1995). Effects of histamine andα-fluoromethylhistidine on brain tumor necrosis factor levels in rats. Inflammation Research. 44(1). 55–57. 9 indexed citations
18.
Alvarez, X.A., et al.. (1994). Effects of neurotoxic lesions in the posterior hypothalamic region on psychomotor activity and learning. Inflammation Research. 43(1-2). 21–23. 11 indexed citations
19.
Alvarez, X.A., et al.. (1994). Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. Inflammation Research. 41(S1). C70–C72. 14 indexed citations
20.
Cacabelos, Ramón & X.A. Alvarez. (1991). Histidine decarboxylase inhibition induced by α-fluoromethylhistidine provokes learning-related hypokinetic activity. Inflammation Research. 33(1-2). 131–134. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Fernández‐Novoa Breakdown of academic impact, for papers by D. Larry Sparks Breakdown of academic impact, for papers by Elina Zotova Breakdown of academic impact, for papers by Claire J. Garwood Breakdown of academic impact, for papers by Beatriz Gomez Perez‐Nievas Breakdown of academic impact, for papers by Jessica L. Restivo Breakdown of academic impact, for papers by Raquel Sánchez‐Varo Breakdown of academic impact, for papers by Beatrice Hauss‐Wegrzyniak Breakdown of academic impact, for papers by Maud Gratuze Breakdown of academic impact, for papers by Michael Hüll
Rankless by CCL
2026